• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Cardiovasc Dis . Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study

tetano

Editor, Senior Moderator
Arch Cardiovasc Dis


. 2021 Mar 2;S1875-2136(21)00049-8.
doi: 10.1016/j.acvd.2021.01.003. Online ahead of print.
Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study


Guillaume Bonnet[SUP] 1 [/SUP], Orianne Weizman[SUP] 2 [/SUP], Antonin Trimaille[SUP] 3 [/SUP], Thibaut Pommier[SUP] 4 [/SUP], Joffrey Cellier[SUP] 5 [/SUP], Laura Geneste[SUP] 6 [/SUP], Vassili Panagides[SUP] 7 [/SUP], Wassima Marsou[SUP] 8 [/SUP], Antoine Deney[SUP] 9 [/SUP], Sabir Attou[SUP] 10 [/SUP], Thomas Delmotte[SUP] 11 [/SUP], Sophie Ribeyrolles[SUP] 12 [/SUP], Pascale Chemaly[SUP] 13 [/SUP], Clément Karsenty[SUP] 9 [/SUP], Gauthier Giordano[SUP] 14 [/SUP], Alexandre Gautier[SUP] 13 [/SUP], Corentin Chaumont[SUP] 15 [/SUP], Pierre Guilleminot[SUP] 16 [/SUP], Audrey Sagnard[SUP] 16 [/SUP], Julie Pastiero[SUP] 16 [/SUP], Nacim Ezzouhairi[SUP] 17 [/SUP], Benjamin Perin[SUP] 14 [/SUP], Cyril Zakine[SUP] 18 [/SUP], Thomas Levasseur[SUP] 19 [/SUP], Iris Ma[SUP] 5 [/SUP], Diane Chavignier[SUP] 20 [/SUP], Nathalie Noirclerc[SUP] 21 [/SUP], Arthur Darmon[SUP] 22 [/SUP], Marine Mevelec[SUP] 20 [/SUP], Baptiste Duceau[SUP] 2 [/SUP], Willy Sutter[SUP] 2 [/SUP], Delphine Mika[SUP] 23 [/SUP], Charles Fauvel[SUP] 15 [/SUP], Théo Pezel[SUP] 24 [/SUP], Victor Waldmann[SUP] 1 [/SUP], Ariel Cohen[SUP] 25 [/SUP], Critical COVID-19 France Investigators



Affiliations

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has led to a public health crisis. Only limited data are available on the characteristics and outcomes of patients hospitalized for COVID-19 in France.
Aims: To investigate the characteristics, cardiovascular complications and outcomes of patients hospitalized for COVID-19 in France.
Methods: The Critical COVID-19 France (CCF) study is a French nationwide study including all consecutive adults with a diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection hospitalized in 24 centres between 26 February and 20 April 2020. Patients admitted directly to intensive care were excluded. Clinical, biological and imaging parameters were systematically collected at hospital admission. The primary outcome was in-hospital death.
Results: Of 2878 patients included (mean±SD age 66.6±17.0 years, 57.8% men), 360 (12.5%) died in the hospital setting, of which 7 (20.7%) were transferred to intensive care before death. The majority of patients had at least one (72.6%) or two (41.6%) cardiovascular risk factors, mostly hypertension (50.8%), obesity (30.3%), dyslipidaemia (28.0%) and diabetes (23.7%). In multivariable analysis, older age (hazard ratio
1.05, 95% confidence interval [CI] 1.03-1.06; P<0.001), male sex (HR 1.69, 95% CI 1.11-2.57; P=0.01), diabetes (HR 1.72, 95% CI 1.12-2.63; P=0.01), chronic kidney failure (HR 1.57, 95% CI 1.02-2.41; P=0.04), elevated troponin (HR 1.66, 95% CI 1.11-2.49; P=0.01), elevated B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide (HR 1.69, 95% CI 1.0004-2.86; P=0.049) and quick Sequential Organ Failure Assessment score ≥2 (HR 1.71, 95% CI 1.12-2.60; P=0.01) were independently associated with in-hospital death.
Conclusions: In this large nationwide cohort of patients hospitalized for COVID-19 in France, cardiovascular comorbidities and risk factors were associated with a substantial morbi-mortality burden.

Keywords: COVID-19; Caractéristiques; Cardiovascular risk factors; Characteristics; Death; Décès; Facteurs de risque cardiovasculaire; SARS-CoV-2.
 
Back
Top Bottom